Logos Global Management LP Q3 2023 significant ownership

Add to watchlist

Logos Global Management LP is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

Logos Global Management LP Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Aeglea BioTherapeutics, Inc.July 18, 20236,350,0008.1%
BICYCLE THERAPEUTICS plcFebruary 14, 20231,435,0004.8%
Dyne Therapeutics, Inc.February 14, 20232,150,0004.1%
Design Therapeutics, Inc.March 31, 20222,797,5015.0%
IDEAYA Biosciences, Inc.March 18, 20222,650,0006.9%
Aligos Therapeutics, Inc.February 14, 2022? ?
Cogent Biosciences, Inc.February 14, 2022150,0000.4%
Kezar Life Sciences, Inc.February 14, 20221,450,0003.0%
Nkarta, Inc.February 14, 2022? ?
Viridian Therapeutics, Inc.\DEFebruary 14, 2022? ?
Eledon Pharmaceuticals, Inc.January 26, 2022? ?
COMPASS Pathways plcDecember 02, 20211,400,0003.4%
Atreca, Inc.November 15, 2021996,5843.3%
Forte Biosciences, Inc.September 13, 2021? ?
ALX ONCOLOGY HOLDINGS INCJune 15, 20213,156,9817.9%
Cogent Biosciences, Inc.November 19, 20201,907,97110.0%
MIRAGEN THERAPEUTICS, INC.November 16, 2020550,00014.1%
MIRAGEN THERAPEUTICS, INC.November 09, 20206,000,0008.8%
Novus Therapeutics, Inc.November 09, 2020224,07115.7%
Celldex Therapeutics, Inc.October 22, 20201,700,0004.3%
Unum Therapeutics Inc.September 08, 20201,928,2915.0%
Keros Therapeutics, Inc.August 31, 20201,350,0006.7%

Compare quarters

Export Logos Global Management LP's holdings

CSVXLS